Next Article in Journal
Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion
Next Article in Special Issue
Timing and Duration of Drug Exposure Affects Outcomes of a Drug-Nutrient Interaction During Ontogeny
Previous Article in Journal
Effect of Moisture on Powder Flow Properties of Theophylline
Pharmaceutics 2010, 2(3), 291-299; doi:10.3390/pharmaceutics2030291

Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients

1, 2 and 1,*
1 Montefiore-Einstein Transplant Center,111 East 210th Street, Bronx, NY 10467, USA 2 School of Pharmacy, State University at Buffalo, 110 Cooke Hall, Buffalo, NY 14215, USA
* Author to whom correspondence should be addressed.
Received: 5 August 2010 / Revised: 23 August 2010 / Accepted: 30 August 2010 / Published: 9 September 2010
View Full-Text   |   Download PDF [60 KB, uploaded 9 September 2010]


Tacrolimus is a calcineurin inhibitor immunosuppressant that has seen considerable use in both adult and pediatric solid organ transplant recipients. Though there is much pharmacokinetic data available for tacrolimus in the adult population, the literature available for children is limited. Furthermore, very little is known about the pharmacogenomic differences in the two patient groups. Based on what information is currently available, clinically significant differences may exist between the two populations in terms of absorption, distribution, metabolism and elimination. In addition, inherent physiological differences exist in the young child including: less effective plasma binding proteins, altered expression of intestinal P-glycoprotein, and increased expression of phase 1 metabolizing enzymes, therefore one would expect to see clinically significant differences when administering tacrolimus to a child. This paper examines available literature in an attempt to summarize the potential pharmacokinetic and pharmacogenomic variability that exists between the two populations.
Keywords: tacrolimus; FK-506; pharmacokinetics; pharmacogenomics; pediatric transplant tacrolimus; FK-506; pharmacokinetics; pharmacogenomics; pediatric transplant
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Marfo, K.; Altshuler, J.; Lu, A. Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients. Pharmaceutics 2010, 2, 291-299.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert